| Netupitant and palonosetron fixed-dose combination versus 5-HT3 receptor antagonists in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: A randomized, open-label, phase IV trial |
Ongoing |
Netupitant and palonosetron, Granisetron transdermal patch, Ondansetron |
4 |
24-1205 |
King Abdullah Medical City (Makkah) |
| A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) |
Ongoing |
Ultomiris (Ravulizumab) |
4 |
ALX-NMO-50 |
King Khalid University Hospital (Riyadh),King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh),King Fahad Medical City (Riyadh) |
| A PHASE III, PROSPECTIVE OPEN-LABEL, MULTI-CENTER SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) PROFILE OF INTRAVENOUS HUMAN NORMAL IMMUNOGLOBULIN (IgG) IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS |
Ongoing |
Golcadomide,BMS-986369 / CC-99282 |
3 |
SKP-LIV_PID_III_2023 |
King Abdulaziz University Hospital (Jeddah), King Fahad Hospital (Jeddah) ,Al-Aziziyah Maternity and Children's Hospital , King Abdulaziz Medical City NG (Jeddah) , King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) |
Ongoing |
Golcadomide,BMS-986369 / CC-99282 |
3 |
CA0731020 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdullah Medical Complex (Jeddah) |
| INTERnational STudy Evaluating Lupus Outcomes after Anifrolumab Real-World Use (INTERSTELLAR): Multi-National, Observational, Prospective, Post-Launch, Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice |
Ongoing |
Semaglutide |
3 |
2241130 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Survey assessing prospective patient’s short-term treatment satisfaction and Quality of Life in patients with Hidradenitis Suppurativa initiated on Cosentyx (Secukinumab) in routine clinical practice in Saudi Arabia |
Ongoing |
Secukinumab |
4 |
CAIN457MSA |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod IV in Adult Participants With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis |
Ongoing |
Efgartigimod IV |
3 |
ARGX-113-2308 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Abdulaziz Medical City NG (Riyadh) |
| Effect and safety of Semaglutide in diabetic kidney transplant recipients with obesity |
Ongoing |
Risankizumab |
3 |
M23-784 |
Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh) |
| A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease |
Ongoing |
Osivelotor |
2/3 |
C5351004 (GBT021601) |
Prince Mohammad Bin Naser Hospital (Jazan), King Abdulaziz Medical City NG (Riyadh) |
| Effect and safety of Semaglutide in diabetic kidney transplant recipients with obesity |
Ongoing |
Anifrolumab |
3 |
2241130 |
Aseer Central Hospital (Abha), International Medical Center (Jeddah), King Khalid University Hospital (Riyadh) |
